Further delineation of BCAP31-linked intellectual disability: description of 17 new families with LoF and missense variants

Sandra Whalen, Marie Shaw, Cyril Mignot, Delphine Héron, Sandra Chantot Bastaraud, Cecile Cieuta Walti, Jan Liebelt, Frances Elmslie, Patrick Yap, Jane Hurst, et al.

► To cite this version:

Sandra Whalen, Marie Shaw, Cyril Mignot, Delphine Héron, Sandra Chantot Bastaraud, et al.. Further delineation of BCAP31-linked intellectual disability: description of 17 new families with LoF and missense variants. European Journal of Human Genetics, 2021, 10.1038/s41431-021-00821-0 . hal-03149040

HAL Id: hal-03149040

<https://hal-amu.archives-ouvertes.fr/hal-03149040>

Submitted on 25 Feb 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Further delineation of *BCAP31*-linked intellectual disability: description of 17 new families with LoF and missense variants

Running title: Description of 17 families with BCAP31 deficiency

Corresponding author:

Sandra Whalen

UF de génétique Clinique et Centre de Reference Anomalies du Développement et Syndromes Malformatifs, APHP.Sorbonne Université, Hôpital Armand Trousseau, Paris, France

Sandra.whalen@aphp.fr

Tel: 0033171738740

Authors:

Sandra Whalen¹, Marie Shaw², Cyril Mignot³, Delphine Héron³, Sandra Chantot Bastaraud⁴, Cecile Cieuta Walti^{5,6}, Jan Liebelt⁷, Frances Elmslie⁸, Patrick Yap⁹, Jane Hurst¹⁰, Elisabeth Forsythe¹⁰, Brian Kirmse¹¹, Jillian Ozmore¹², Alessandro Mauro Spinelli¹³, Olga Calabrese¹³, Thierry Billette de Villemeur¹⁴, Anne Claude Tabet¹⁵, Jonathan Levy¹⁵, Agnes Guet¹⁶, Manoëlle Kossorotoff¹⁷, Benjamin Kamien¹⁸, Jenny Morton¹⁹, Anne McCabe¹⁹, Elise Brischoux-Boucher²⁰, Annick Raas-Rothschild²², Antonella Pini²³, Renée Carroll², Jessica N. Hartley²⁴, Care4Rare Canada Consortium, Patrick Frosk²⁴, Anne Slavotinek²⁵, Kristen Truxal²⁶, Carroll Jennifer²⁶, Annelies Dheedene²⁷, Hong Cui²⁸, Vishal Kumar^{29,30}, Glen Thomson³¹, Florence Riccardi^{21,33}, Jozef Gecz^{*2,32}, Laurent Villard^{*21,33}

1. UF de Génétique Clinique et Centre de Reference Anomalies du Développement et Syndromes Malformatifs, APHP.Sorbonne Université, Hôpital Trousseau, Paris, France

2. Adelaide Medical School and Robinson Research Institute, The University of Adelaide, South Australia 5005, Australia

3. Département de Génétique et de Cytogénétique et Centre de Référence Déficiences Intellectuelles de Causes Rares, APHP.Sorbonne Université, Paris, France

- 34 4. Département de Génétique, UF de Génétique Chromosomique, APHP, Hôpital
35 Armand Trousseau, Paris, France
- 36 5. Institut Jérôme Lejeune, Paris, France
- 37 6. IUSSS de l'Estrie-CHUS Université de Sherbrooke, Canada
- 38 7. South Australian Clinical Genetics Service, Women's and Children's Hospital,
39 Adelaide, Australia
- 40 8. South West Thames Regional Genetics Service, St George's University Hospitals,
41 London, UK
- 42 9. Genetic Health Service New Zealand (Northern Hub), Auckland 1023, New
43 Zealand
- 44 10. Department of Clinical Genetics, Great Ormond Street Hospital For Children NHS
45 Foundation Trust, London, United Kingdom of Great Britain and Northern Ireland
- 46 11. Division of Medical Genetics, Department of Pediatrics, University of Mississippi
47 Medical Center, Jackson, MS, USA
- 48 12. Medical Genetics, Dartmouth-Hitchcock medical center, Lebanon, New
49 Hampshire, USA
- 50 13. Medical Genetics Unit, University of Modena and Reggio Emilia, Modena, Italy
- 51 14. Sorbonne Université, service de neuropédiatrie, Hôpital Trousseau, APHP.SU,
52 Inserm U1141, Paris, France
- 53 15. UF de Cytogénétique, Département de génétique, APHP, Hôpital Robert Debré,
54 Paris, France
- 55 16. Service de Néonatalogie et Pédiatrie, APHP, Hôpital Louis-Mourier, Colombes,
56 France
- 57 17. Département de Neurologie pédiatrique, AP-HP, Hôpital Necker-Enfants-Malades,
58 Paris, France
- 59 18. Genetic Services of Western Australia, King Edward Memorial Hospital, Subiaco,
60 Australia
- 61 19. West Midlands Regional Clinical Genetics Service and Birmingham Health
62 Partners, Birmingham Women's and Children's Hospitals NHS Foundation Trust, UK
- 63 20. Centre de Génétique Humaine, Université de Franche-Comté, Besançon, France
- 64 21. Département de génétique médicale, AP-HM, Hôpital d'enfants La Timone,
65 Marseille, France
- 66 22. Institute for Rare Diseases, Edmond and Lily Safra Children Hospital, Sheba
67 Medical Center, Israel
- 68 23. Child Neurology and Psychiatry Unit, IRCCS Istituto delle Scienze Neurologiche,
69 Bologna, Italy
- 70 24. Biochemistry & Medical Genetics, Max Rady College of Medicine, Rady Faculty
71 of Health Sciences, University of Manitoba, Winnipeg, Canada
- 72 25. Medical Genetics, Benioff Children's Hospital Oakland, Division of Genetics,
73 Department of Pediatrics, University of California, UCSF Benioff Children's Hospital,
74 San Francisco, USA
- 75 26. Division of Genetic and Genomic Medicine, Nationwide Children's Hospital and
76 Research Institute, The Ohio State University, Columbus, Ohio, USA
- 77 27. Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

- 78 28. GeneDx, 207 Perry Parkway, Gaithersburg, MD 20877, USA
79 29. Department of Radiology and Biomedical Imaging, University of California, San
80 Francisco, 1001 Potrero Ave., San Francisco, CA 94110, USA
81 30. Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco,
82 California, USA
83 31. Department of Paediatric Radiology, Starship Children's Hospital, Auckland, New
84 Zealand
85 32. South Australian Health and Medical Research Institute, Adelaide, South
86 Australia 5000, Australia
87 33. Aix Marseille Université, Inserm, MMG, U1251, Marseille, France.

88
89 *these authors contributed equally to this work

90

91 **Conflict of interest:** the authors declare that they have no conflict of interest.

92

93 **Abstract**

94 The *BCAP31* gene, located at Xq28, encodes BAP31 which plays a role in ER-to-
95 Golgi anterograde transport. To date, *BCAP31* pathogenic variants have been
96 reported in 12 male cases from 7 families (six loss of function (LoF) and one
97 missense). Patients had severe intellectual disability (ID), dystonia, deafness, and
98 central hypomyelination, delineating a so-called DDCH syndrome (Deafness,
99 Dystonia and Cerebral Hypomyelination). Female carriers are mostly asymptomatic
100 but may present with deafness. *BCAP31* is flanked by the *SLC6A8* and *ABCD1*
101 genes. Contiguous deletions of *BCAP31* and *ABCD1* and/or *SLC6A8* have been
102 described in 12 patients. Patients with deletions including *BCAP31* and *SLC6A8*
103 have the same phenotype as *BCAP31* patients. Patients with deletions of *BCAP31*
104 and *ABCD1* have Contiguous *ABCD1* and *DXS1375E/BCAP31* Deletion Syndrome
105 (CADDS), and demonstrate a more severe neurological phenotype with cholestatic
106 liver disease and early death. We report 17 novel families, 14 with intragenic
107 *BCAP31* variants (LoF and missense) and three with a deletion of *BCAP31* and
108 adjacent genes (comprising 2 CADDS patients, one male and one symptomatic
109 female). Our study confirms the phenotype reported in males with intragenic LoF
110 variants and shows that males with missense variants exhibit a milder phenotype.
111 Most patients with a LoF pathogenic *BCAP31* variant have permanent or transient
112 liver enzyme elevation. We further demonstrate that carrier females (n=10) may have
113 a phenotype comprising LD, ID and/or deafness. The male with CADDS had a severe
114 neurological phenotype, but no cholestatic liver disease; and the symptomatic female
115 had moderate ID and cholestatic liver disease.

116

117 **Key words:** *BCAP31*, dystonia, hearing loss, liver disease, DDCH syndrome,
118 intellectual disability
119
120

INTRODUCTION

The *BCAP31* gene (MIM 300398) is located at Xq28 and encodes B-cell-receptor-associated protein 31 (BAP31), a ubiquitous 31 kDa chaperone protein highly expressed in neurons (1). It is the most abundant of endoplasmic reticulum (ER) membrane proteins (2) and plays a role in regulation of apoptosis, protein transport and degradation. BAP31 has a role in the export of secreted proteins (3,4), and their targeting to the ER-associated-degradation pathway (ERAD) (5,6). BAP31 also serves as a cargo receptor for the export of transmembrane proteins. (1).

In 2013, Cacciagli et al (7) described a specific phenotype associated with *BCAP31* loss of function (LoF) anomalies in seven males from three families with severe to profound developmental delay (DD) or intellectual disability (ID), dystonia, seizures, sensorineural hearing loss (SNHL) and central myelination delay which defined the DDCH syndrome (for Deafness, Dystonia and Cerebral Hypomyelination, MIM 300475). In all instances, the pathogenic *BCAP31* variants were inherited from asymptomatic mothers. Functional studies were undertaken on patient fibroblasts and supported the evidence that BAP31 plays a role in ER-to-Golgi exchanges. No evidence of accumulation of misfolded proteins or activation of either UPR or cell-death programs was found. It was hypothesized that the key role of ER protein trafficking in the myelination process (8) could explain the white matter abnormalities. Four additional male patients from three families with *BCAP31* LoF anomalies and a similar phenotype were subsequently reported (9–11). Vittal et al reported two affected brothers (twins) with a 6 bp deletion in c.261_266delGCTTCT (c.60_65delGCTTCT according to reference transcript NM_001139441.1) resulting in a protein change of p.(Leu87_Leu89delinsPhe) (p.(Leu20_Leu22delinsPhe)

according to the protein produced by transcript NM_001139441.1) that can be considered as a missense variant (12). The phenotype of one of the two brothers is milder than in previously described patients with *BCAP31* LoF variants, as he acquired partial language and basic academic skills.

Liver enzymes were elevated in half of the reported patients, either permanently or intermittently, sometimes during febrile episodes. Patients with pathogenic *BCAP31* variants/intragenic deletions did not display cholestasis or hepatic failure, except one with acute liver cytolysis and cholestasis concomitant to an episode of intestinal necrosis (11). All female carriers reported to date were asymptomatic, except one with isolated SNHL (9).

BCAP31 is flanked by *SLC6A8* (MIM 300036) on its centromeric side, and *ABCD1* (MIM 300371) on its telomeric side. Contiguous deletions of *BCAP31* and *ABCD1* and/or *SLC6A8* have been described. Pathogenic *ABCD1* LoF variants are responsible of X-linked adrenoleukodystrophy, a neurodegenerative condition that affects the central nervous system white matter and the adrenal cortex, that can reveal itself in childhood (cerebral form) or adulthood (adrenomyeloneuropathy) (13).

The childhood onset of the disease is characterized by progressive impairment of cognition, behavior, vision, hearing, and motor function. However, neurodegeneration does not start before 2.7 years. Pathogenic *SLC6A8* LoF variants result in cerebral creatine deficiency and the patients display mild to severe ID, seizures and behavioral problems (14). Sensorineural hearing loss, dystonia and chorea are rare.

Patients with deletions of *BCAP31* and *ABCD1* have Contiguous *ABCD1* and *DXS1375E* (*BCAP31*) Deletion Syndrome (CADDs, MIM 300475) (15). The six male patients described with CADDs had common signs with DDCH, such as severe DD, dystonia, white matter abnormalities and deafness. However, all of these six patients

171 had chronic cholestatic liver disease, and a more severe course of the disease, as all
172 died in the first year of life (15–19). The only symptomatic female with a deletion
173 encompassing both *BCAP31* and *ABCD1* reported to date is a 9-year-old girl with
174 severe ID, autism spectrum disorder, microcephaly and deafness, but without white
175 matter anomalies or dystonia (20).

176 Six patients with a deletion including *BCAP31* and *SLC6A8* have been described
177 (including a family of four patients described by Cacciagli et al) (7,18,21). Their
178 phenotype was more severe than most patients with pathogenic *SLC6A8* variants,
179 and they had symptoms and signs similar to *BCAP31* patients, such as dystonia,
180 choreoathetosis, SNHL and white matter abnormalities, which are unusual in cerebral
181 creatine deficiency. Thus, most of their phenotype was ascribed to the deletion of
182 *BCAP31* (7).

183
184 We assessed 17 novel families with *BCAP31* anomalies, 14 families with intragenic
185 LoF or missense variants (16 males and 9 symptomatic females) and three families
186 with a deletion of *BCAP31* and adjacent genes (comprising two CADD5 patients, one
187 male and a symptomatic female). The symptomatic female carriers had SNHL and/or
188 DD/ID. We also describe two asymptomatic female carriers with somatic mosaicism
189 which is particularly relevant for genetic counselling.

191 **PATIENTS AND METHODS**

192 Male and female individuals with *BCAP31* variants and deletions were recruited from
193 different cohorts through national and international collaborations. For two families,
194 the patients were part of a cohort of cerebral palsy patients.

Genetic testing was performed by chromosomal microarray (n=3 deletions), whole-genome sequencing (n=1), whole-exome sequencing (n=8), TrueSight One gene panel (n=1), X chromosome sequencing (n=1), targeted gene panel for ID (n=1), targeted gene panel for mitochondrial diseases (n=1), or direct Sanger sequencing of *BCAP31* (n=1).

Variants were annotated using NM_001139441.1 as a reference sequence and were classified according to the ACMG criteria (22,23). Exons are numbered according to Cacciagli et al. 2013. and correspond to transcript ENST00000458587.8.

Intragenic variants were submitted to the gene variant database LOVD at <https://databases.lovd.nl/shared/individuals/BCAP31> (Patients 1 to 11: individuals 00315922 to 00315932, Patient 12: individual 00317967, Patient 13: individual 00315934, Patient 14: individual 00314857, Patients 15 to 18: individuals 00314696 to 00314699). Large deletions including *BCAP31* and adjacent genes were submitted to ClinVar at <https://www.ncbi.nlm.nih.gov/clinvar> (Patients 19 to 21: individuals SCV001450740 to SCV001450742).

Each patient's referring physician filled out a table with detailed general data, family history, pregnancy and labor, neonatal period, developmental milestones, neurological signs, behavioral and epilepsy history, and other detailed clinical history or features (senses, liver, cardiac and respiratory). When possible, pictures and/or videos of the patients and brain MRI were reviewed.

Parental written informed consent was obtained for all affected patients. Genetic testing was performed in accordance with the respective national ethics guidelines and approved by the local authorities in the participating study centers.

RESULTS

Male patients with intragenic variants of *BCAP31*

Male patients with LoF variants

A total of 12 males from 11 families had intragenic LoF variants (Table 1, P1 to P12 Families 1 to 11, and Figure 1), that were all maternally inherited except one that was *de novo*. Somatic mosaicism was found in the mother of P12.

The median age of these patients at last examination was 9 years 5 months (2.4 to 28 years), and all but one were alive at the time of the study. All patients presented with severe to profound DD, none achieved walking, all had absent or limited speech, and all but one had limited or no purposeful use of hands. Neurological examination showed dystonic postures and/or choreic movements (12/12), microcephaly (7/11) and increased muscle tone/pyramidal signs (6/11). The diagnosis of cerebral palsy was initially considered in P5. Seizures were seen in 3/12 patients (petit mal for one, not detailed in the 2 others). The disease appeared to be progressive for two patients. Brain MRI was abnormal in 9/11 patients. White matter (WM) anomalies were the most frequent (7/11), and were described as reduced WM volume, myelination delay, hypomyelination and WM hyperintensities. These anomalies disappeared with time in one patient at the age of 12 years. Other reported anomalies were cortical atrophy (4/11), thin corpus callosum (3/9), atrophy of basal ganglia and thalami (2/11) and hypoplastic cerebellar vermis (2/11).

Moderate to profound SNHL was seen in 9/10 (with normal inner ear CT scan for one patient) and strabismus was frequent (6/11). Small stature (-2SD or below) was seen in 7/12 patients, with weight on -2SD or below in 6/12. Some common facial features were noted such as hypotonic face and deep-set eyes. Unexplained fever was reported in two patients. No major cardio-respiratory anomalies were reported.

Liver enzymes were increased in 8/10, either transiently (n=4) or permanently (n=4). Two patients (P7 and P12) underwent liver biopsy, that showed mild to moderate mononuclear portal tract inflammatory infiltrate consistent with mild chronic hepatitis in P7, and mitochondrial inclusions with a regular/periodic pattern in P12. The latter finding could represent abnormalities of cristae and gave an overall morphology of crystalline inclusions. Mitochondrial complex activities were normal in the fibroblast of two brothers (P2 and P3). CSF neurotransmitters showed mild cerebral folate deficiency (5-MTHF 30 nM, normal 40-187 nM) in one patient (P10). He was treated with oral folinic acid with minimal clinical effect.

Detailed molecular results of these patients are presented in Figure 1. Interestingly, the variant c.365_366del was found in unrelated patients P5 and P10.

Male patients with missense variants

Four male patients from two families had missense variants (Table 2, P14 to P17, Families 13 and 14, and Figure 1). Median age at last examination was 19.25 years (3 years to 36 years) and all but one were alive at the time of the study.

The patients had mild (1/4), moderate (1/4) or severe (2/4) DD/ID. Unsupported sitting was achieved in 3/3, assisted walking for 2/3, all had partial language skills (words for three, sentences for one), and three patients attended a special needs school, one was reported to be able to read simple texts. Dystonic postures and/or choreic movements were seen in all patients and two had increased muscle tone/pyramidal signs. The diagnosis of cerebral palsy was initially considered in these patients. The use of hands was reported to be purposeful for one. Microcephaly was seen in 1/3. None of these patients had seizures or apparent progressive course of the disease. For P14, brain MRI was normal at 14 months.

SNHL was seen in P14 with normal inner ear CT scan, and conductive hearing loss was found in P15. No ophthalmological data was obtained and no liver dysfunction was reported. Two patients had persistent failure to thrive. P14 had a hypotonic face. His supposedly affected uncle had deep-set eyes with high and narrow nasal bridge, similar to other DDCH patients. No specific facial features were noted for the patients of family 14.

In P14 (Family 13), the NM_001139441.1:c.47T>A ; p.(Val16Asp) missense variant affects a highly conserved amino-acid within the B-cell receptor-associated 31-like domain, is not reported in gnomAD and is estimated disease causing by pathogenicity predictors. This variant is not reported in gnomAD.

In P15 (Family 14), X chromosome exome sequencing identified 16 variants in total, including the *BCAP31* variant Hg38: chrX:153715545G>T, NM_001139441.1:c.338C>A. After *in silico* analysis, all variants except *BCAP31* were not flagged for follow up. This variant affects a moderately conserved serine residue located in the BAP31 superfamily domain. It is not present in gnomAD and has a CADD (phred) of 23.5. Preliminary data in P18, a symptomatic female (direct cousin of P15), suggests that her fibroblasts have larger/more swollen ER than controls, and abnormal golgi staining (data not shown). The most substantial evidence for the pathogenicity of the variant in this family is its presence in all symptomatic individuals and carrier mothers. However, according to ACMG criteria, these two missense variants remain classified as VUS to date.

Symptomatic female carriers of intragenic *BCAP31* anomalies

Females with LoF variants.

Three carrier mothers were symptomatic, two with SNHL (family 2 and 4), and one with apparent mild ID (family 3).

P13 was the only affected individual in family 12 and had severe ID, achieved sitting at 18 months, walking at 4 years, and had limited speech at 7 years. She had microcephaly and lower limb spasticity, but no dystonia, chorea or seizures. She had hearing loss and persistent strabismus. She had deep set eyes with high and narrow nasal bridge. Brain MRI at 3 years old showed thin corpus callosum, enlarged cisterna magna, enlarged subarachnoid frontal space but no white matter anomalies. Liver function was normal. X-inactivation studies in peripheral blood showed significant bias at the FRAXA locus (93/7 %) and 88/12 % at the HUMARA locus. Her mother was found to have a somatic mosaicism for the pathogenic *BCAP31* variant (3%).

Females with missense variants.

In Family 13, the four confirmed female carriers had isolated SNHL. X-inactivation chromosome studies in peripheral blood were inconclusive, showing moderate skewing in one (90/10), no skewing for the second and uninformative results in the third.

In Family 14, a carrier female (Table 2, P18) had global DD, acquired walking at age 17 months and had language delay. She had mild ID, attended a special needs school and could read. She had mild ataxic gait and drop attacks, but no dystonia or chorea. Mild conductive hearing loss was noted in infancy as well as atypical retinal pigmentation. No specific facial features were noted. No data was obtained for liver function. X-inactivation was random in peripheral blood, but skewed toward the variant allele in cultured fibroblasts, as sequencing of the *BCAP31* transcript from

fibroblast cDNA, showed only presence of the variant transcript. Functional studies were undertaken on the fibroblasts showing mildly altered ER and Golgi as described by Cacciagli et al but were not statistically significant (data not shown).

Patients with deletion of *BCAP31* and adjacent genes (Table 3 and Figure 2)

Male patient with non-CADDS deletion

P19 (Family 15), had a *de novo* deletion including *BCAP31*, *SLC6A8*, *DUSP9*, *PNCK* (NC_000023.10:g.(152886255_152976269)del). He had profound DD, infantile spasms, pyramidal signs but no dystonia or chorea. Brain MRI at 2 years old showed abnormal WM and global atrophy. SNHL was diagnosed at birth. Growth was normal including OFC. He had no cholestatic liver disease, however developed reversible acute liver failure during a lung infection that lead to sepsis.

Male patient with CADDS

P20 (Family 16) had a *de novo* 60 kb deletion including *BCAP31*, *ABCD1* and *PLXNB3* (NC_000023.10:g.(152982350_153041544)del). He had severe DD with no acquired milestones at 16 months, choreic movements and frequent opisthotonus. Brain MRI at 1 month and 10 months showed thalamic hyperintensities with normal WM. He had permanent moderate liver enzyme elevation, but no cholestasis. He had normal hearing, bilateral strabismus, episodes of unexplained fever and recurrent respiratory infections. He was born with severe IUGR followed by severe growth impairment. He was treated for adrenal and exocrine pancreatic deficiency. Lung CT was undertaken at 15 months because of chronic hypoxia and showed unexplained interstitial lung infiltrate. He died of respiratory failure at 16 months.

Symptomatic female with a deletion of BCAP31 and ABCD1

P21 (Family 17) had a deletion including *SLC6A8*, *BCAP31*, exon 1 of *ABCD1*, *DUSP9*, *PCNK* (NC_000023.10:g.(152882907_152991027)del). She was adopted and parental analysis could not be performed. She had moderate ID, walked at 24 months and said a few words at 3 years. She had no seizures and no microcephaly. Brain MRI at 15 months showed diffuse WM abnormalities predominant in periventricular region and global atrophy. Spectroscopy showed reduced creatine peak at 50% due to *SLC6A8* deletion. She also had a SNHL, strabismus and hypermetropia. Liver dysfunction was reported with chronic cholestasis, moderate hepatic failure, transient episodes of liver enzyme elevation, and liver biopsy showed signs of cholangiopathy.

Discussion

Males with intragenic pathogenic *BCAP31* variants

The phenotype of the 12 males of this study with intragenic LoF variants is similar to that of previously described cases, hereby confirming a homogeneous clinical involvement in all reported cases to date. The pathogenic *BCAP31* variants were inherited in 10 families, and one mother displayed somatic mosaicism (patient 12). All male patients displayed severe DD/ID with no walking, absent or very limited language skills and dystonia or chorea. Microcephaly and increased muscle tone/pyramidal signs were frequent. Seizures were present in few individuals and two patients had an apparently progressive course of disease which has not yet been reported. Common facial features were noted in some patients with hypotonic face and deep set eyes with narrow and high nasal bridge, the latter seemed to be more obvious with time (Figure 3). Physicians considered the diagnosis of cerebral palsy in

P5 (LoF variant), in individuals of Family 14 (missense variant) and in a presumably affected relative of P14. Hence, it would be relevant to search for pathogenic *BCAP31* variants in patients presenting with unexplained cerebral palsy. As in previous patients, brain MRI frequently showed abnormal WM (Figure 4). P2 showed surprising results over time, with myelination delay at 9 months, WM hyperintensities at 10 years, and normalized WM at 12 years old. It would be interesting to repeat the MRI in other patients to further characterize WM changes during the course of the disease. Other signs were reported but inconsistent, including cortical atrophy, thin corpus callosum, basal ganglia anomalies (atrophic, small, hyperintense on T2 weighted MRI sequences), and hypoplastic cerebellar vermis. SNHL was a frequent feature, and the inner ear was radiologically normal in two patients, it would be interesting to confirm this observation in additional patients.

As for molecular results, we report the first recurrent pathogenic LoF variant to our knowledge (c.365_366del). We report two further families with missense variants and suggestive clinical presentation, but that remain classified as VUS. The ID in the four males of these families was less severe than in LoF patients, similar to the patients described by Vittal et al (12) thus a milder functional effect of the missense variants could be speculated to explain the milder intellectual disability. However, more patients and functional assessment of these variants are needed to support their involvement in the phenotype.

Symptomatic female carriers of intragenic *BCAP31* variants

Our results substantiate the findings of Albanyan et al (9) who described a carrier female with SNHL. Six females in our study also had SNHL, two with LoF variants, and four with missense variants. Interestingly, Rosenberg et al (24) identified a

patient with non-syndromic hearing loss (the sex of the patient was not mentioned) harboring a *de novo* duplication including *BCAP31* and *SLC6A8*. Altogether, these data suggest that *BCAP31* anomalies should be considered in females with non-syndromic hearing loss. It would be relevant for genetic counselling for female carriers, to consider the risk of having a severely affected male. Sensorineural hearing loss (SNHL) being the most common congenital sensory deficit, with an estimated prevalence of 2–3 cases per 1,000 individuals it seems important to rule out other causes, genetic or not, before confirming the implication of *BCAP31*. Approximately half of SNHL in children is due to genetic causes, with 70% being non-syndromic. Variations in the *GJB2* gene is the most common cause of nonsyndromic genetic SNHL in many populations, however there is high genetic and allelic heterogeneity, with over 100 implicated genes, which can be recessive, dominant, X-linked or mitochondrial (25,26).

We also report the first female carriers with mild (two carrier mothers) or severe ID (one proband). We have limited data describing the brain MRI in females, and further data is necessary to speculate about WM abnormalities in these cases. No specific facial features were noted in female carriers except for patient 13 who had severe ID and displayed deep set eyes and narrow nasal bridge.

Patients with deletion of *BCAP31* and adjacent genes (*CADDS* and non-*CADDS*)

The phenotype of the male patient of this study with a non-*CADDS* deletion including *BCAP31* and *SLC6A8* was similar to patients with a pathogenic intragenic LoF *BCAP31* variant, and more severe than patients with *SLC6A8* deficiency, supporting

the evidence that *BCAP31* is the major gene responsible for the phenotype, as discussed by previous authors (7,19).

The phenotype of the male patient of our study with CADDs is consistent with previously published cases, with severe DD, dystonia, choreic movements and early death. Unlike other CADDs patients, WM was normal, however thalamic hyperintensities were noted, and hearing was normal. Unreported signs were seen in our patient, such as unexplained lung interstitial infiltrate and exocrine pancreatic deficiency.

Finally, we report the second female with a deletion of *ABCD1* and *BCAP31*. Both patients had ID, moderate in this study and severe with ASD for the patient described by Firouzabadi et al (20). Both had SNHL. Neither had dystonia or chorea. The patient in this study also had cholestatic liver disease and WM abnormalities, as in male CADDs patients.

The large deletions in the three patients of this study also involve adjacent genes, as in previously reported patients. It is possible that other genes deleted in our patients and those of the literature, such as *PNCK*, *DUSP9*, *PLXNB3*, could also contribute to the phenotype, however no data is available to support or exclude this hypothesis to date.

Liver phenotype in *BCAP31* deficiency

Patients with intragenic *BCAP31* anomalies have frequent liver enzyme elevation, either permanently or intermittently, sometimes during febrile episodes. P20 (non-CADDs deletion) displayed a unique episode of acute hepatic failure during valproic acid treatment. *BCAP31* has been shown to play a role in lipid metabolism in the liver. Alteration of *BCAP31* in mice leads to elevated lipid storage and subsequent

inflammation (27,28). Interestingly, two patients with LoF *BCAP31* variants displayed anomalies on liver biopsy, with liver inflammation for P7, and mitochondrial inclusions suggesting a mitochondrial disorder for P12. Shimizu et al (11) and Albanyan et al (9) had already suggested that *BCAP31* deficiency shared similarities with mitochondrial disorders, regarding their patients who presented with bilateral hyperintensities of globus pallidus and mitochondrial anomalies on muscle biopsy (9) or complex I deficit in fibroblasts (11). Further exploration in patients with *BCAP31* deficiency would be of interest to understand the physiopathology, especially regarding the liver, and to search for signs of mitochondrial dysfunction.

No patients with *BCAP31* intragenic anomalies or non-CADDS deletions had chronic cholestatic liver disease, as described in the patients with CADDS. This cholestatic disease is suggested to be linked to the deletion of both *BCAP31* and *ABCD1* with a supposed synergistic effect, however there is no explanation of the mechanism up to date. The male patient in our study with CADDS had no cholestatic disease at 16 months, but had permanent moderate liver enzyme elevation. Liver biopsy in P21, the affected female CADDS carrier, showed signs of cholangiopathy.

Further data is needed to understand the potential liver dysfunction in *BCAP31* deficiency and CADDS patients. In the meantime, we suggest monitoring liver function carefully in *BCAP31* patients and it is suggested to administer with caution potential hepatotoxic drugs. Valproic acid should be avoided in *BCAP31* patients regarding the liver failure in one of our patients. No complication has been reported for acetaminophen to date, and patient 20 frequently received acetaminophen for unexplained fever with no evident change of his liver function, however careful monitoring could be suggested.

In summary, we report 17 novel families with pathogenic *BCAP31* variants, including 14 families with LoF variants, two families with missense variants and three families with large deletions (two with CADDs and one non-CADDs). We confirm the phenotype of *BCAP31* deficiency in males, with a possible milder effect of missense variants. We describe symptomatic female carriers with SNHL and/or ID, and more studies are needed to further delineate their phenotype. In most affected male patients, the variant is inherited from the mother, and the description of two asymptomatic carrier females with somatic mosaicism prompts to give careful genetic counselling concerning the recurrence risk.

Acknowledgments and funding

- Hong Cui is an employee of GeneDx, Inc
- Jozef Gecz was supported by NHMRC grants APP1155224 and APP1091593 and Channel 7 Children's Research Foundation.
- Anne Slavotinek's research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number U01HG009599. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Amendola et. al. American Journal of Human Genetics. 2018 Sep 6;103(3):319-327. doi: 10.1016/j.ajhg.2018.08.007

REFERENCES

1. Manley HA, Lennon VA. Endoplasmic reticulum membrane-sorting protein of lymphocytes (BAP31) is highly expressed in neurons and discrete endocrine cells. J Histochem Cytochem Off J Histochem Soc. oct 2001;49(10):1235-43.
2. Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, et al. Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem. 16 févr 2001;276(7):5152-65.

- 496 3. Annaert WG, Becker B, Kistner U, Reth M, Jahn R. Export of cellubrevin from
497 the endoplasmic reticulum is controlled by BAP31. *J Cell Biol.* 15 déc
498 1997;139(6):1397-410.
- 499 4. Paquet M-E, Cohen-Doyle M, Shore GC, Williams DB. Bap29/31 Influences
500 the Intracellular Traffic of MHC Class I Molecules. *J Immunol.* 15 juin
501 2004;172(12):7548-55.
- 502 5. Geiger R, Andritschke D, Friebe S, Herzog F, Luisoni S, Heger T, et al. BAP31
503 and BiP are essential for dislocation of SV40 from the endoplasmic reticulum to the
504 cytosol. *Nat Cell Biol.* nov 2011;13(11):1305-14.
- 505 6. Wakana Y, Takai S, Nakajima K, Tani K, Yamamoto A, Watson P, et al. Bap31
506 Is an Itinerant Protein That Moves between the Peripheral Endoplasmic Reticulum
507 (ER) and a Juxtanuclear Compartment Related to ER-associated Degradation.
508 Linstedt A, éditeur. *Mol Biol Cell.* mai 2008;19(5):1825-36.
- 509 7. Cacciagli P, Sutura-Sardo J, Borges-Correia A, Roux J-C, Dorboz I,
510 Desvignes J-P, et al. Mutations in BCAP31 cause a severe X-linked phenotype with
511 deafness, dystonia, and central hypomyelination and disorganize the Golgi apparatus.
512 *Am J Hum Genet.* 5 sept 2013;93(3):579-86.
- 513 8. Roboti P, Swanton E, High S. Differences in endoplasmic-reticulum quality
514 control determine the cellular response to disease-associated mutants of proteolipid
515 protein. *J Cell Sci.* 1 nov 2009;122(Pt 21):3942-53.
- 516 9. Albanyan S, Al Teneiji A, Monfared N, Mercimek-Mahmutoglu S. BCAP31-
517 associated encephalopathy and complex movement disorder mimicking
518 mitochondrial encephalopathy. *Am J Med Genet A.* juin 2017;173(6):1640-3.
- 519 10. Rinaldi B, Van Hoof E, Corveleyn A, Van Cauter A, de Ravel T. BCAP31-
520 related syndrome: The first de novo report. *Eur J Med Genet.* 19 juill 2019;103732.
- 521 11. Shimizu K, Oba D, Nambu R, Tanaka M, Oguma E, Murayama K, et al.
522 Possible mitochondrial dysfunction in a patient with deafness, dystonia, and cerebral
523 hypomyelination (DDCH) due to *BCAP31* Mutation. *Mol Genet Genomic Med.* 2020
524 Mar;8(3):e1129.
- 525 12. Vittal P, Hall DA, Dames S, Mao R, Berry-Kravis E. BCAP31 Mutation Causing
526 a Syndrome of Congenital Dystonia, Facial Dysmorphism and Central Hypomyelination
527 Discovered Using Exome Sequencing. *Mov Disord Clin Pract.* avr 2016;3(2):197-9.
- 528 13. Engelen M, Kemp S, de Visser M, van Geel BM, Wanders RJ, Aubourg P, et
529 al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for
530 diagnosis, follow-up and management. *Orphanet J Rare Dis.* 2012;7(1):51.
- 531 14. van de Kamp JM, Betsalel OT, Mercimek-Mahmutoglu S, Abulhoul L,
532 Grünwald S, Anselm I, et al. Phenotype and genotype in 101 males with X-linked
533 creatine transporter deficiency. *J Med Genet.* juill 2013;50(7):463-72.
- 534 15. Corzo D, Gibson W, Johnson K, Mitchell G, LePage G, Cox GF, et al.
535 Contiguous Deletion of the X-Linked Adrenoleukodystrophy Gene (ABCD1) and
536 DXS1357E: A Novel Neonatal Phenotype Similar to Peroxisomal Biogenesis
537 Disorders. *Am J Hum Genet.* juin 2002;70(6):1520-31.
- 538 16. Calhoun ARUL, Raymond GV. Distal Xq28 microdeletions: clarification of the
539 spectrum of contiguous gene deletions involving ABCD1, BCAP31, and SLC6A8 with
540 a new case and review of the literature. *Am J Med Genet A.* oct
541 2014;164A(10):2613-7.
- 542 17. Iwasa M, Yamagata T, Mizuguchi M, Itoh M, Matsumoto A, Hironaka M, et al.
543 Contiguous ABCD1 DXS1357E deletion syndrome: report of an autopsy case.
544 *Neuropathol Off J Jpn Soc Neuropathol.* juin 2013;33(3):292-8.
- 545 18. Osaka H, Takagi A, Tsuyusaki Y, Wada T, Iai M, Yamashita S, et al.

Contiguous deletion of SLC6A8 and BAP31 in a patient with severe dystonia and sensorineural deafness. *Mol Genet Metab.* mai 2012;106(1):43-7.

19. van de Kamp JM, Errami A, Howidi M, Anselm I, Winter S, Phalin-Roque J, et al. Genotype-phenotype correlation of contiguous gene deletions of SLC6A8, BCAP31 and ABCD1. *Clin Genet.* févr 2015;87(2):141-7.

20. Firouzabadi SG, Kariminejad R, Vameghi R, Darvish H, Ghaedi H, Banihashemi S, et al. Copy Number Variants in Patients with Autism and Additional Clinical Features: Report of VIPR2 Duplication and a Novel Microduplication Syndrome. *Mol Neurobiol.* nov 2017;54(9):7019-27.

21. Anselm IM, Alkuraya FS, Salomons GS, Jakobs C, Fulton AB, Mazumdar M, et al. X-linked creatine transporter defect: A report on two unrelated boys with a severe clinical phenotype. *J Inher Metab Dis.* févr 2006;29(1):214-9.

22. Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho Y-Y, et al. Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria. *Genet Med Off J Am Coll Med Genet.* 2017;19(10):1105-17.

23. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med Off J Am Coll Med Genet.* mai 2015;17(5):405-24.

24. Rosenberg C, Freitas ÉL, Uehara DT, Auricchio MTBM, Costa SS, Oiticica J, et al. Genomic copy number alterations in non-syndromic hearing loss. *Clin Genet.* avr 2016;89(4):473-7.

25. Alford RL, Arnos KS, Fox M, Lin JW, Palmer CG, Pandya A, et al. American College of Medical Genetics and Genomics guideline for the clinical evaluation and etiologic diagnosis of hearing loss. *Genet Med Off J Am Coll Med Genet.* avr 2014;16(4):347-55.

26. Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, et al. Expert specification of the ACMG/AMP variant interpretation guidelines for genetic hearing loss. *Hum Mutat.* 2018;39(11):1593-613.

27. Wu Z, Yang F, Jiang S, Sun X, Xu J. Induction of Liver Steatosis in BAP31-Deficient Mice Burdened with Tunicamycin-Induced Endoplasmic Reticulum Stress. *Int J Mol Sci.* 4 août 2018;19(8).

28. Xu J-L, Li L-Y, Wang Y-Q, Li Y-Q, Shan M, Sun S-Z, et al. Hepatocyte-specific deletion of BAP31 promotes SREBP1C activation, promotes hepatic lipid accumulation, and worsens IR in mice. *J Lipid Res.* 2018;59(1):35-47.

Table 1: Clinical and molecular features of patients with intragenic pathogenic LoF *BCAP31* variants. Reference transcript: NM_001139441.1.

abN, abnormal; BG, basal ganglia; C, chronic; CM, cisterna magna; CC, corpus callosum; G, Gastrostomy tube; ID, intellectual disability; I, intermittent; LD, learning disabilities; mat, maternal; nd, not determined; nr, non relevant; P, patient; SNHL, sensorineural hearing loss; subA, subarachnoidal; WM, white matter; VH, vermis hypoplasia

Table 2: Clinical and molecular features of patients with missense *BCAP31* variants. Reference transcript: NM_001139441.1.

CC, corpus callosum; ID, intellectual disability; mat, maternal; nd, not determined; P, patient; SNHL, sensorineural hearing loss.

Table 3: Clinical and genetic features of patients with large deletions including *BCAP31*. Reference transcript: NM_001139441.1.

CC, corpus callosum; DD, developmental delay; G, Gastrostomy tube; mat, maternal; nd, not determined; nr, non relevant; P, patient; SNHL, sensorineural hearing loss; VD, ventricular dilatation; WM, white matter.

Figure 1: scheme of *BCAP31* gene showing the LoF and missense variants identified in published patients and those of our study.

The variants identified in patients of our study are located above the gene, and those previously reported are underneath the gene. Reference transcript: NM_001139441.1. Exons are numbered according to Cacciagli et al. 2013. and correspond to transcript ENST00000458587.8. Full splice variant denomination is NC_000023.11(NM_001139441.1):g.153723152C>T for P2 and P3; and NC_000023.11(NM_001139441.1):g.153702006C>T for P8.

Figure 2: Scheme of *BCAP31* and flanking genes, showing large deletions of *BCAP31* identified in patients of this study and in the literature.

On the top, non-CADDS patients, with deletions including *BCAP31* and adjacent genes in 5' (excluding *ABCD1*). On the bottom, CADDS patients with deletions including *BCAP31* and *ABCD1*. Reference transcript: NM_001139441.1. Exons are numbered

according to Cacciagli et al. 2013. and correspond to transcript
ENST00000458587.8.

Figure 3: Facial features of *BCAP31* patients. The males P6 and P9 have a LoF variant of *BCAP31*. P14 has a missense variant. P13 is a female with a LoF variant. There does not seem to be a specific facial gestalt for *BCAP31* anomalies. Some common features have been noted with deep set eyes, as P6 and P13, hypotonic face as seen in P6, P9 and P14, high nasal bridge for P6, high and narrow bridge for P9 and P13.

Figure 4: Cerebral MRI of patients 1, 11 and 19. A) Patient 1 (LoF intragenic pathogenic variant). At 2 years old (A1: axial FLAIR, A2, A3, A4: axial T2): signal hyperintensity in the peritrigonal white matter (see arrows in A1), small thalami (see arrows in A3), small cerebral peduncles (see arrows in A2), paired T2 hyperintensities in the dorsal pons (see arrows in A4). **B) Patient 11 (LoF intragenic pathogenic variant).** At 8 months old (B1: sagittal T1, B2: axial FLAIR): markedly decreased white matter as evidenced by a thin corpus callosum (B1 and B2) as well as the sylvian fissures nearly abutting the lateral ventricles (see arrows in B2). **C) Patient 19 (deletion of *BCAP31* and adjacent genes).** At 6 months (C1: sagittal T1, C2: axial T2): decreased white matter, myelination delay, cortical atrophy, thin corpus callosum and ventricular dilatation. At 2 years old (C3: sagittal T2, C4: axial T2): increased white matter anomalies, marked cortical atrophy, vermian atrophy and ventricular dilatation.

Table 1: Clinical and molecular features of patients with intragenic pathogenic LoF *BCAP31* variants. Reference transcript: NM_001139441.1.

Literature		This report												Total	This report
Patient ID	6 pat, 4 families	P1 Family 1	P2 Family 2	P3 Family 2	P4 Family 3	P5 Family 4	P6 Family 5	P7 Family 6	P8 Family 7	P9 Family 8	P10 Family 9	P11 Family 10	P12 Family 11	18 males 15 families	P13 (female) Family 12
Age at last examination	3y-22y	2y3m	21y6m	10y6m	2y6m	2y6m	28y	14y	5y9m	9y7m	4y7m (died 4y9m)	8y11m	2y10m	Median 9y1m	7y5m
BCAP31 variant		c.3G>C	c.92+1G>A	c.92+1G>A	c.466C>T	c.365_366del	c.445A>T	c.664dup	c.702+1G>A	c.733_736del	c.365_366del	c.705_*4del	NC_000023.9: g.(152982315_152988064)del		c.380_383dup
Inheritance	2 <i>de novo</i> others inherited	mat	mat	mat	mat	mat	mat	mat	<i>de novo</i>	mat	mat (de novo in mother)	nd	mat (mosaic)	3 <i>de novo</i> in 15 families	mat (mosaic)
Affected carrier mother	1 SNHL	-	SNHL		LD mild ID	SNHL	-	-	nr	-	-	nd	Episodes of nystagmus	3 SNHL 1 mild ID	-
Severity of DD/ID	6/6 severe to profound	severe	severe	severe	severe	severe	severe	severe	severe/profound	profound	profound	severe	severe	18/18 severe to profound	severe
Walking	0/6	-	-	-	-	-	-	-	-	-	-	-	-	0/18	+ 4y
Absent language	6/6	+	+	+	+	+	+	+	+	+	+	+	+	18/18	-
Seizures	3/6	-	-	-	-	-	+	+ febrile	-	+	-	-	-	6/18	-
Dystonia/chorea	6/6	+	+	+	+	+	+	+	+	+	+	+	+	17/18	-
Spasticity	5/5	-	-	-	-	+	+	+	+	nd	+	+	-	11/16	+
Hearing loss	6/6	+ SNHL	+ SNHL	-	nd	+ SNHL	+	nd	+ mixed	+	+ SNHL	+ SNHL	+ SNHL	16/18	+
OFC <-2SD	5/6	- (-2 SD)	-	+ (-3 SD)	+ (-5 SD)	+ (-4 SD)	- (-2 SD)	-	+ (-2,2 SD)	nd	+ (-7 SD)	+ (-3,5 SD)	+ (-3 SD)	13/18	+ (-3,5 SD)
Elevated liver enzyme	4/4	-	+ (C)	+ (I)	+ (I)	+	-	+ (C)	+ (I)	+ (I)	+ (C)	+ (C)	+ (C)	14/16	nd
Unexplained episodic fever	3/3	-	-	-	+	-	+	-	-	nd	+	-	-	6/14	-
Age at MRI		2y	9m, 10y, 12y	5m	15m	3y	nd	11y	8m	8m	5m, 15m	8m	3m		3,5y
Abnormal WM	4/4	+	+ at 9m nl at 12y	nd	+	+	-	+	+	-	-	+	-	11/15	-
Other MRI findings	4 cortical atrophy 1 CC atrophy 2 abN BG 1 cerebellar atrophy	abN BG	VH	nd	-	cortical atrophy, thin CC	VH	cortical atrophy, thin CC, abN BG	cortical atrophy, thin CC	cortical atrophy	-	-	-		thin CC, enlarged CM and subA spaces

abN, abnormal ; BG, basal ganglia; C, chronic; CM, cisterna magna; CC, corpus callosum; G, Gastrostomy tube; ID, intellectual disability; I, intermittent; LD, learning disabilities; mat, maternal; nd, not determined; nr, non relevant; P, patient; SNHL, sensorineural hearing loss; subA, subarachnoidal; WM, white matter; VH, vermis hypoplasia

Table 2: Clinical and molecular features of patients with missense *BCAP31* variants. Reference transcript: NM_001139441.1.

Patient ID	Literature 2 patients 1 family (Vittal et al)	P14 Family 13	P15 Family 14	P16 (uncle of P15) Family 14	P17 (uncle of P15) Family 14	Total 6 patients 3 families	P18 (female) Family 14 (cousin of P15, niece of P16 and P17)
Sex	M	M	M	M	M	M	F
Age last examination	21y (twins)	3y	32y	36y	29y	19y10m	19y
Variant	c.261_266del p.(Leu87_Leu89delinsPhe)	c.47T>A p.(Val16Asp)	c.338C>A p.(Ser113Tyr)	c.338C>A p.(Ser113Tyr)	c.338C>A p.(Ser113Tyr)		c.338C>A p.(Ser113Tyr)
Inheritance	mat	mat	mat	mat	mat	mat	mat
Affected carrier mother	-	SNHL	late onset seizures	nd	nd	1 SNLH, 1 late onset seizures	late onset seizures
Severity of ID	Moderate to severe	mild	severe	severe	moderate	Moderate to severe	mild
Sitting	0/2	+	+	nd	+	2/4	+
Walking	0/2	-	-	-	+ ataxic	1/6	+ 17m
Language	1/2 (partial)	+ words	+ words communicates with ipad	+ words dysarthria	+ sentences dysarthria	5/6	+ delayed dysarthria
Seizures	nd	-	-	-	-	0/4	+ drop attacks
Dystonia/chorea	2/2	+	+	+	+	6/6	-
Spasticity	nd	nd	-	+	-	1/3	-
Hearing loss	2/2	+ SNHL	+ conductive	-	-	4/6	-
OFC <-2SD	nd	-	-	+	nd	1/3	-
Elevated Liver enzyme	nd	-	-	nd	nd	0/1	nd
Unexplained episodic fever	nd	-	-	-	-	0/4	-
Age at MRI	nd	14m					18y
Abnormal MRI	1/1	-	nd	nd	nd	1/2	-
Other	Cerebral MRI showed delayed myelination, atrophy of posterior ocipital lobes, thin CC, hypoplasia of superior cerebellar vermis	SNHL in 3 other female carriers. An uncle of P15 presumably had the same condition although DNA was not available for testing	Recurrent pneumonia. Swallowing difficulties.	Collapse due to severe dehydration and hypernatremia at 6m Died at 36y of twisted bowel			ataxic gait

CC, corpus callosum; ID, intellectual disability; mat, maternal; nd, not determined; P, patient; SNHL, sensorineural hearing loss.

Table 3: clinical and genetic features of patients with large deletions including *BCAP31*.
Reference transcript: NM_001139441.1

	Literature	This report		Total	This report
Patient ID	7 patients (7 families)	P19 Family 15	P20 Family 16	9 male patients	P21 (female) Family 17
Age	4m-11m	3y	16m (deceased)	4m-16m	3y
Variant	See figure 2	NC_000023.10: g.(152886255_ 152976269)del	NC_000023.10: g.(152982350_ 153041544)del		NC_000023.10: g.(152882907_ 152991027)del
Inheritance	<i>2/5 de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>4/7 de novo</i>	nd
Affected carrier mother	nd	nr	nr	nd	nd
Severity of DD	<i>7/7 severe to profound</i>	profound	profound	<i>9/9 severe to profound</i>	moderate
Walking	nr	-	nr		+ 2y
Absent or limited language	nr	+	nr		+ rare words
Seizures	3/6	+ spasms	-	4/8	-
Dystonia/chorea	1/6	-	+	2/8	-
Spasticity	nd	+	-	1/2	-
Hearing loss	5/7	+	-	6/9	+
OFC <-2SD	2/2	-	+	3/4	-
Liver dysfunction	<i>7/7 cholestasis</i>	reversible acute liver failure	moderate enzyme elevation	9/9	cholestasis, intermittent enzyme elevation, hepatic failure
Cholangiopathy on Liver biopsy	3/3	nd	nd	3/3	+
Adrenal dysfunction	3/7 ?	-	+	4/9	nd
Age at MRI		2y	2m, 10m		15m
Abnormal WM	4/5	+	-	5/6	+
Other cMRI findings	1 thin CC, 1 VD	cerebellar atrophy	pulvinar hyperintensity		cerebellar atrophy, VD

CC, corpus callosum; DD, developmental delay; G, Gastrostomy tube; mat, maternal; nd, not determined; nr, non relevant; P, patient; SNHL, sensorineural hearing loss; VD, ventricular dilatation; WM, white matter.